PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6726182

Rubella virus: structural and non-structural proteins.

D S Bowden·E G Westaway
View original source ↗Export metadata ↓

Abstract

Rubella virus was rapidly concentrated and purified using polyethylene glycol 6000 as the precipitating agent. Electrophoresis in slab gels defined three structural proteins present in equimolar amounts, with mol. wt. of 59000 (E1), 43000 to 48000 (heterogeneous E2) and 34000 (core protein, C). E1 and E2 were glycosylated; different distributions of labelled carbohydrates within the broad band of E2 indicated that the slower migrating region was enriched in complex oligosaccharides. In infected cells, the counterparts to E1 and E2 were labelled with [3H]mannose and both migrated in gels as sharp bands, indicating that the heterogeneity observed in virion E2 was produced during virus maturation. After radioimmunoprecipitation of infected cell extracts with convalescent rubella serum, the intracellular equivalents of E1, E2 and C were readily defined in gels, as well as several putative non-structural proteins. Four of these were defined more clearly and without resort to immunoprecipitation by labelling with [35S]methionine during hypertonic treatment of infected cells at 24 h; their mol. wt. were 200 000, 150 000, 87 000 and 75 000. Pulse-chase experiments under these conditions showed that the largest ( ns200 ) was apparently cleaved to ns150 .

Explore related subjects

GlycoproteinsMolecular WeightRubella virusViral ProteinsVirionVirus ReplicationJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D S Bowden, E G Westaway. 1984. Rubella virus: structural and non-structural proteins.. https://doi.org/10.1099/0022-1317-65-5-933

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Synthetic glycobiology: Exploits in the Golgi compartment.

The challenge of engineering glycosylation has been confronted by synthetic chemists, biochemists and cell biologists, each with the primary goal of optimizing glycoconjugates for therapeutic applications. In nature, glycans are constructed by glycosyltransferases that are organized in an assembly line in the endoplasmic reticulum and Golgi compartment. Recent insights into the domain architecture, localization and regulation of glycosyltransferases have provided a platform for engineering their position within the secretory pathway and access to substrates. Using this knowledge, glycosyltransferase assembly lines have been redesigned for the production of specific glycan structures using protein engineering and chemical approaches. These efforts epitomize the emerging field of 'synthetic glycobiology'.

Glycoproteins↗
PubMed2006

Strategies for the preparation of homogenous glycoproteins.

The majority of human proteins are glycosylated, and many of them are known to be involved in important biological processes. This class of proteins is often expressed as a heterogeneous mixture of glycoforms, rendering the isolation of individual species for various studies a difficult task. Recent advances in the development of glycoprotein synthesis have provided promising strategies, which include enzymatic, chemical and in vivo suppressor tRNA methods to obtain homogenous products. Nevertheless, there are many remaining challenges to overcome in both the chemical and biochemical approaches to efficiently obtain homogenous glycoproteins for glycobiology research and for the production of pharmaceutical products.

Glycoproteins↗
PubMed2006

A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry.

The early expression of Epap-1 (early pregnancy associated protein), a 90 kDa anti-HIV-1 active glycoprotein, in the first trimester placental tissue suggests that it is one of the innate immune factors/proteins protecting the fetus from HIV infections. In the present investigation, we have cloned and expressed Epap-1 in bacterial and baculovirus expression systems. The recombinant Epap-1 as well as native Epap-1 shows a conserved molecular mode of action. These proteins exhibit significant antiviral activity and inhibit the cell fusion reaction between gp120 expressing HeLa (HL2/3) cells and T cell line (SupT1). Further, the rhodamine labeled Epap-1 specifically bound to gp120 expressed on the surface of HL2/3 cells during fusion reaction thereby inhibiting viral entry. Analysis of the interacting gp120 epitopes revealed that Epap-1 binds specifically to epitopes of gp120, recognizing constant-5 (C5) region and the variable-3 (V3) epitope of gp120 expressed on HL2/3 cells; It exhibits specific interaction with C5 region of cell-free virus in four HIV-1 isolates suggesting that the molecular interaction of Epap-1 is specific and is highly conserved in binding to gp120 leading to inhibition of viral entry. Epap-1 can thus be a very efficient natural protection mechanism against cell-free and cell-associated viral infections during early pregnancy.

Glycoproteins↗